Circulating retinol-binding protein 4 concentrations in patients with coronary artery disease and patients with type 2 diabetes mellitus

  • Mohammad Jafar Mahmoudi
  • Maryam Mahmoudi
  • Fereydoon Siassi
  • Mona Hedayat
  • Parvin Pasalar
  • Maryam Chamari
  • Hassan Abolhassani
  • Nima Rezaei
  • Ali-Akbar Saboor-Yaraghi
Original Article


Circulating Retinol-Binding Protein 4 (RBP4) has recently been identified as a marker of insulin resistance. We tested this hypothesis in patients with coronary artery disease (CAD), patients with type 2 diabetes mellitus (T2DM), and in non-diabetic control subjects. We studied plasma RBP4 levels and RBP4-to-transthyrethin (TTR) ratio, estimating the excess circulating RBP4 in proportion to TTR, in 45 individuals divided into three groups (15 CAD, 15 T2DM, and 15 controls). Plasma RBP4 levels were significantly lower in patients with T2DM than in non-diabetic control subjects (P = 0.05). The RBP4/TTR ratio was not statistically different between the groups. There was no difference in plasma RBP4 levels and RBP4/TTR ratio between non-diabetic CAD patients and control subjects or those with and without metabolic syndrome. No significant associations were found between RBP4 and RBP4/TTR ratio, as dependent parameters, with markers of the metabolic syndrome and lipid metabolism. RBP4 does not seem to be a valuable marker for identification of the metabolic syndrome or insulin resistance in patients with T2DM or CAD.


Atherosclerosis Diabetes mellitus Metabolic syndrome Retinol-binding protein 


  1. 1.
    Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316:129–39.PubMedCrossRefGoogle Scholar
  2. 2.
    von Eynatten M, Humpert PM. Retinol-binding protein-4 in experimental and clinical metabolic disease. Expert Rev Mol Diagn. 2008;8:289–99.CrossRefGoogle Scholar
  3. 3.
    Raghu P, Sivakumar B. Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis. Biochim Biophys Acta. 2004;1703:1–9.PubMedGoogle Scholar
  4. 4.
    Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006;354:2552–63.PubMedCrossRefGoogle Scholar
  5. 5.
    Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2006;29:2457–61.PubMedCrossRefGoogle Scholar
  6. 6.
    Qi Q, Yu Z, Ye X, Zhao F, Huang P, Hu FB, Franco OH, Wang J, Li H, Liu Y, Lin X. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab. 2007;92:4827–34.PubMedCrossRefGoogle Scholar
  7. 7.
    Broch M, Vendrell J, Ricart W, Richart C, Fernandez-Real JM. Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects. Diabetes Care. 2007;30:1802–6.PubMedCrossRefGoogle Scholar
  8. 8.
    von Eynatten M, Lepper PM, Liu D, Lang K, Baumann M, Nawroth PP, Bierhaus A, Dugi KA, Heemann U, Allolio B, Humpert PM. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia. 2007;50:1930–7.CrossRefGoogle Scholar
  9. 9.
    Ingelsson E, Sundstrom J, Melhus H, Michaelsson K, Berne C, Vasan RS, Riserus U, Blomhoff R, Lind L, Arnlov J. Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Atherosclerosis. 2009;206:239–44.PubMedCrossRefGoogle Scholar
  10. 10.
    Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–97.Google Scholar
  11. 11.
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Yao-Borengasser A, Varma V, Bodles AM, Rasouli N, Phanavanh B, Lee MJ, Starks T, Kern LM, Spencer 3rd HJ, Rashidi AA, McGehee Jr RE, Fried SK, Kern PA. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab. 2007;92:2590–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, Cline GW, Befroy D, Zemany L, Kahn BB, Papademetris X, Rothman DL, Shulman GI. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci USA. 2007;104:12587–94.PubMedCrossRefGoogle Scholar
  14. 14.
    Janke J, Engeli S, Boschmann M, Adams F, Bohnke J, Luft FC, Sharma AM, Jordan J. Retinol-binding protein 4 in human obesity. Diabetes. 2006;55:2805–10.PubMedCrossRefGoogle Scholar
  15. 15.
    Erikstrup C, Mortensen OH, Nielsen AR, Fischer CP, Plomgaard P, Petersen AM, Krogh-Madsen R, Lindegaard B, Erhardt JG, Ullum H, Benn CS, Pedersen BK. RBP-to-retinol ratio, but not total RBP, is elevated in patients with type 2 diabetes. Diabetes Obes Metab. 2009;11:204–12.PubMedCrossRefGoogle Scholar
  16. 16.
    Sasaki H, Iwasaki T, Kato S, Tada N. High retinol/retinol-binding protein ratio in noninsulin-dependent diabetes mellitus. Am J Med Sci. 1995;310:177–82.PubMedCrossRefGoogle Scholar
  17. 17.
    Akbay E, Muslu N, Nayir E, Ozhan O, Kiykim A. Serum retinol binding protein 4 level is related with renal functions in Type 2 diabetes. J Endocrinol Invest. 2010;33:725–9.PubMedGoogle Scholar
  18. 18.
    Cabre A, Lazaro I, Girona J, Manzanares J, Marimon F, Plana N, Heras M, Masana L. Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. J Intern Med. 2007;262:496–503.PubMedCrossRefGoogle Scholar
  19. 19.
    Henze A, Frey SK, Raila J, Tepel M, Scholze A, Pfeiffer AF, Weickert MO, Spranger J, Schweigert FJ. Evidence that kidney function but not type 2 diabetes determines retinol-binding protein 4 serum levels. Diabetes. 2008;57:3323–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Mallat Z, Simon T, Benessiano J, Clement K, Taleb S, Wareham NJ, Luben R, Khaw KT, Tedgui A, Boekholdt SM. Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women. J Clin Endocrinol Metab. 2009;94:255–60.PubMedCrossRefGoogle Scholar
  21. 21.
    Bobbert T, Raila J, Schwarz F, Mai K, Henze A, Pfeiffer AF, Schweigert FJ, Spranger J. Relation between retinol, retinol-binding protein 4, transthyretin and carotid intima media thickness. Atherosclerosis. 2010;213:549–51.PubMedCrossRefGoogle Scholar
  22. 22.
    Kloting N, Graham TE, Berndt J, Kralisch S, Kovacs P, Wason CJ, Fasshauer M, Schon MR, Stumvoll M, Bluher M, Kahn BB. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 2007;6:79–87.PubMedCrossRefGoogle Scholar
  23. 23.
    Lee JW, Im JA, Lee HR, Shim JY, Youn BS, Lee DC. Visceral adiposity is associated with serum retinol binding protein-4 levels in healthy women. Obesity (Silver Spring). 2007;15:2225–32.CrossRefGoogle Scholar

Copyright information

© Research Society for Study of Diabetes in India 2012

Authors and Affiliations

  • Mohammad Jafar Mahmoudi
    • 1
  • Maryam Mahmoudi
    • 2
  • Fereydoon Siassi
    • 2
  • Mona Hedayat
    • 1
    • 3
  • Parvin Pasalar
    • 4
    • 5
  • Maryam Chamari
    • 2
  • Hassan Abolhassani
    • 3
  • Nima Rezaei
    • 3
    • 6
  • Ali-Akbar Saboor-Yaraghi
    • 2
  1. 1.Division of Cardiology, Department of Internal Medicine, School of MedicineTehran University of Medical SciencesTehranIran
  2. 2.Department of Nutrition and Biochemistry, School of Public HealthTehran University of Medical SciencesTehranIran
  3. 3.Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical CenterTehran University of Medical SciencesTehranIran
  4. 4.Endocrinology and Metabolism Research CenterTehran University of Medical SciencesTehranIran
  5. 5.Department of Biochemistry, School of MedicineTehran University of Medical SciencesTehranIran
  6. 6.Molecular Immunology Research Center; and Department of Immunology, School of MedicineTehran University of Medical SciencesTehranIran

Personalised recommendations